Clinical trial sa lagundi at tawa-tawa bilang supplement COVID-19 treatment aprubado na ng DOST

By Dona Dominguez-Cargullo August 14, 2020 - 05:44 PM

Inaprubahan na ng Department of Science and Technology ang clinical trial sa lagundi at tawa-tawa para maipanggamot sa COVID-19.

Ayon sa Malakanyang, dagdag ito sa melatonin, convalescent plasma at virgin coconut oils na sumasailalim din sa trial.

Sinabi ni Presidential Spokesperson Harry Roque, habang patuloy ang paghikayat ng pamahalaan sa publiko na sundin ang mga health protocol, tuloy din ang pagkilos ng government scientists upang makahanap ng gamot laban sa COVID-19.

Kalahok din ang bansa sa pamamagitan ng DOST sa pag-develop ng bakuna laban sa sakit.

Bahagi aniya ang Pilipinas sa World Health Organization Solidarity Trials para sa COVID-19 treatments.

Sa ngayon ani Roque, pinag-aaralan na din ni Pangulong Rodrigo Duterte ang rekomendasyon na magtayo ng Virology Science and Technology Institute sa bansa.

Magsisilbi itong premiere research institute sa virology and diseases upang mapalakas ang vaccine development ng Pilipinas.

 

 

TAGS: covid pandemic, COVID-19, covid19 treatment, department of health, general community quarantine, Health, Inquirer News, lagundi, Modified enhanced community quarantine, Modified general community quarantine, News in the Philippines, Radyo Inquirer, State of Emergency, Tagalog breaking news, tagalog news website, Tawa-Tawa, covid pandemic, COVID-19, covid19 treatment, department of health, general community quarantine, Health, Inquirer News, lagundi, Modified enhanced community quarantine, Modified general community quarantine, News in the Philippines, Radyo Inquirer, State of Emergency, Tagalog breaking news, tagalog news website, Tawa-Tawa

Disclaimer: The comments uploaded on this site do not necessarily represent or reflect the views of management and owner of Cebudailynews. We reserve the right to exclude comments that we deem to be inconsistent with our editorial standards.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.